Rocket Doctor AI Inc. filed its audited annual financial statements for fiscal year 2025 on May 4, reporting $1.739 million in total revenue, 87% gross margins, and a US in-network patient reach spanning more than 21 million covered lives across California, New York, and Maryland. It’s the company’s first full year of consolidated reporting after its acquisition of Rocket Doctor Inc. in Q2 2025. Revenue was up from $10,990 in 2024.
Quarter-over-quarter momentum was a defining feature. Revenue ran $512,755 in Q2, $529,123 in Q3, then jumped to $697,340 in Q4, a 30%-plus sequential gain in that final quarter. CEO Dr. Essam Hamza described 2025 as a foundational year, a transition from proving the concept to demonstrating the potential scalability of the physician-led model.
Yazan Al Homsi, a Vancouver-based venture capitalist, discloses a financial interest in Rocket Doctor AI held through his firm, Founders Round Capital. He is an investor in the company only, not a business partner or operator. His investment thesis has centred on unit economics: the platform’s ability to deliver healthcare access at a fraction of the cost of physical infrastructure while sustaining margins that beat sector averages by a wide margin. Al Homsi’s career, from his upbringing in Saudi Arabia through McGill University and over a decade at PricewaterhouseCoopers in the Middle East and North Africa, built the financial due diligence framework he now applies to small-cap healthcare technology investments.
The Margin Story Is the Real Headline
The revenue total of $1.74 million is a starting point. The number that matters for the investment thesis is the gross margin. Rocket Doctor AI reported 87% gross margins for the full year. Q4 came in at 84%. The modest compression came from the revenue mix shift after the Rocket Doctor Inc. acquisition and the associated scaling of the digital health platform. The digital health sector average sits around 53%.
That’s a 34-percentage-point gap over sector peers. It’s structural, not cyclical.
The reason is straightforward: the model is a physician marketplace. Incremental revenue comes from onboarding clinicians, not building physical facilities. Variable costs grow far more slowly than revenue. Fundamental Research Corp, which covers the stock with a Buy rating and a fair value of C$1.86, noted that 2025 revenue came in 8% above its estimate. At roughly C$0.63 at the time of its update, the stock was trading at 6x forward EBITDA versus an 18x sector average, a 65% discount. Maxim Group initiated coverage in January 2026 with a Buy rating and a C$3.00 price target. That makes it the second analyst house covering the name.
US Payer Network: The Infrastructure Built in 2025
Here’s the context that the revenue headline doesn’t capture. US operations contributed less than 3% of 2025 revenue. The 21 million covered lives now accessible through in-network payer agreements are almost entirely unmoneyed so far. That network was built during 2025 and is the commercial engine for 2026.
In October, the company announced multiple in-network agreements covering more than 13 million lives across California and New York, including commercial, Medicare Advantage, and Veterans populations. Q4 added another 4.6 million covered lives and launched operations in Maryland, with Dr. Suzanne Caccamese appointed as Maryland Medical Lead. By year-end, total in-network reach stood at 21 million members across approximately 20 insurers and payers.
In October 2025, Rocket Doctor was also awarded over US$500,000 as part of a US$2 million Small Business Innovation Research grant from the National Institutes of Health to advance its AI-driven medical history collection technology. Federal research grants don’t get awarded based on investor enthusiasm. They require rigorous technical review. That NIH award signals that Rocket Doctor’s clinical AI capabilities have met a credibility threshold that’s independent of commercial traction.
What Rocket Doctor AI Actually Is
This is worth stating clearly because earlier coverage conflated portfolio companies. Rocket Doctor AI is a physician-built, AI-powered digital health platform and marketplace that enables physicians to independently launch and manage virtual or hybrid in-person practices. It has nothing to do with Edumentors, a UK-based online tutoring platform that is a separate investment in Al Homsi’s portfolio. The two companies share an investor and nothing else.
The platform has facilitated over 750,000 patient visits through a network of more than 350 physicians. Its Global Library of Medicine, a clinically validated decision support system built with input from hundreds of physicians worldwide, underpins its AI capabilities. In November 2025, the company acquired Alea Health Holdings, a conversational AI-powered mental health platform. The acquisition closed in January 2026 and opens a strategic entry point into the Middle East, the UAE in particular.
Capital and Commercial Momentum Post Year-End
After the close of FY2025, Rocket Doctor closed a non-brokered private placement for approximately $5.2 million, upsized due to investor demand, and it closed January 22, 2026. Warrant exercises added another $1.24 million. Total post-year-end capital raises came to roughly $6.44 million, with no near-term dilution expected per the Fundamental Research coverage note.
In June 2026, the company announced a strategic marketing partnership with Rick Ware Racing and FINTEKK AP covering the 2026 NASCAR Cup Series and other nationally televised motorsport events. It’s a brand-awareness play targeting insured patient populations through mass-media channels, with a lower cost-per-acquisition profile than direct digital marketing.
The Math That Makes 2026 the Year to Watch
Al Homsi’s small-cap investment framework has always been about finding the point where operational proof meets institutional underpricing. The FY2025 results show a platform with 750,000-plus patient visits proven, 87% gross margins, and a US payer network covering 21 million lives while generating less than 3% of revenue from those relationships.
Dr. Hamza laid out the 2026 priorities clearly: expanding US payer partnership depth, multi-state expansion, white-label partnerships, and deeper AI integration across clinical workflows. The arithmetic is direct. If a meaningful fraction of 21 million in-network members becomes active at $18 per US visit and 87% margins, the revenue picture looks very different from the $1.74 million 2025 baseline. Al Homsi’s cross-border investment activities, spanning his Vancouver and UAE operations, position him to identify the kinds of payer-driven healthcare platforms that are gaining traction across both North American and Middle Eastern markets simultaneously.